Aura Biosciences, Inc. (NASDAQ:AURA) Receives $22.75 Average PT from Brokerages

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been assigned an average rating of “Buy” from the eight research firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $22.75.

A number of equities analysts have recently commented on the company. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. JMP Securities set a $19.00 target price on Aura Biosciences in a research note on Wednesday, March 26th. Citigroup restated an “outperform” rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, HC Wainwright set a $25.00 price objective on shares of Aura Biosciences in a research report on Tuesday, March 25th.

Insider Activity

In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of the business’s stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the sale, the insider now directly owns 179,313 shares of the company’s stock, valued at $984,428.37. The trade was a 3.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,104 shares of company stock valued at $221,486 over the last quarter. 5.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC lifted its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares during the period. State Street Corp raised its holdings in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares during the last quarter. Geode Capital Management LLC raised its holdings in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Aura Biosciences in the 3rd quarter worth approximately $1,037,000. Finally, Franklin Resources Inc. boosted its stake in shares of Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after purchasing an additional 215,597 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Stock Down 0.7 %

AURA stock opened at $5.36 on Friday. The company’s 50-day moving average price is $6.76 and its two-hundred day moving average price is $8.18. The firm has a market cap of $269.21 million, a P/E ratio of -3.10 and a beta of 0.43. Aura Biosciences has a 12 month low of $4.84 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). Equities analysts predict that Aura Biosciences will post -1.66 EPS for the current year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.